Superselective Adrenal Arterial Embolization for Refractory Hypertension: A Proof-of-Concept Study
This study tests a new procedure called superselective adrenal arterial embolization (SAAE) for patients with high blood pressure that does not respond well to medications. In this procedure, doctors use imaging to locate and block blood vessels supplying the adrenal glands, which produce hormones that can raise blood pressure.
Key Objective: This trial is testing whether blocking blood flow to the adrenal glands can safely lower blood pressure in patients whose hypertension has not improved with standard medications.
Who to Consider: Patients with essential hypertension that remains uncontrolled despite taking multiple blood pressure medications should consider enrolling in this study.
Trial Parameters
Brief Summary
The subjects of this study were patients with essential refractory hypertension. The purpose of this study is to evaluate the safety and efficacy of superselective adrenal arterial embolization (SAAE) in patients with primary refractory hypertension and to explore the possibility of SAAE in patients with primary refractory hypertension.After the subject completes the SAAE, an 8-week follow-up will be conducted to assess the safety and effectiveness of the SAAE.
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years, no gender restrictions; * Primary refractory hypertension: Taking three antihypertensive drugs, including a - diuretic, with an average office systolic blood pressure ≥150 mmHg measured three times; * Duration of hypertension greater than 6 months; * Standing plasma aldosterone and renin activity not below the lower limit of the unit's reference range; * Signed informed consent form. Exclusion Criteria: * Morning cortisol level \< 4.3 µg/dL; estimated glomerular filtration rate (eGFR) \< 45 mL/min/1.73 m²; serum potassium level \> 5.5 mmol/L; * Type 1 diabetes, uncontrolled hyperthyroidism, malignant arrhythmias, malignant tumors, decompensated heart failure, severe liver dysfunction, severe hematological diseases, severe obstructive sleep apnea syndrome, history of myocardial infarction, syncope, cerebral hemorrhage, or cerebral infarction within the past 3 months; * Pregnant women or those planning to conceive within the next year; * Presence of